Cellerys AG
🇨🇭Switzerland
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Phase 1
Recruiting
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: CLS12311 lowDrug: CLS12311 mediumDrug: CLS12311 highDrug: uncoupled RBCs
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Cellerys AG
- Target Recruit Count
- 135
- Registration Number
- NCT06430671
- Locations
- 🇨🇿
Neurologická klinika 2. LF UK a FN Motol, Praha 5, Czech Republic
🇨🇿RS Centrum - Neurologická klinika, Praha, Czech Republic
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Neurologická Klinika, Prague, Czech Republic
© Copyright 2025. All Rights Reserved by MedPath